CN Patent

CN118786216A — 一种抑制PCSK9基因表达的RNAi剂及其应用

Assigned to CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd · Expires 2024-10-15 · 2y expired

What this patent protects

一种抑制PCSK9基因表达的RNAi剂及其应用，本发明涉及一种修饰的双链RNAi剂及其应用，具体涉及一种抑制PCSK9基因表达的双链RNAi剂及其药物组合物，以及使用所述双链RNAi剂或其药物组合物用于治疗由PCSK9表达介导的疾病的应用。

USPTO Abstract

一种抑制PCSK9基因表达的RNAi剂及其应用，本发明涉及一种修饰的双链RNAi剂及其应用，具体涉及一种抑制PCSK9基因表达的双链RNAi剂及其药物组合物，以及使用所述双链RNAi剂或其药物组合物用于治疗由PCSK9表达介导的疾病的应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN118786216A
Jurisdiction
CN
Classification
—
Expires
2024-10-15
Drug substance claim
No
Drug product claim
No
Assignee
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.